Marksans Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Marksans Pharma has filed a routine regulatory certificate for the quarter ended March 31, 2026. The company's Registrar and Transfer Agent, Bigshare Services Private Limited, has confirmed compliance with SEBI dematerialization regulations. The certificate verifies that all securities received for dematerialization were properly processed and confirmed to depositories, listed on the relevant stock exchange, and that physical share certificates were mutilated and cancelled. Additionally, the RTA confirms that depository names were substituted in the register of members within the required 15-day timeframe. This is a standard quarterly compliance filing required under SEBI regulations.
This is a routine regulatory compliance filing with no direct impact on stock price or shareholder value. It confirms proper handling of share dematerialization processes by the company's RTA.